GSK Q1 beats estimates

GSK first quarter profits and revenue both beat expectations driven by its shingles and meningitis treatments, among others.

The company posted revenue of £7bn against expectations of £6.5bnm according to company-compiled estimates. Adjusted operating profit rose 8% to £2.1bn as GSK also maintained full-year guidance.

Its shingles vaccine, Shingrix, generated sales of £833m, beating estimates of £829m.

Reporting by Frank Prenesti for Sharecast.com